
MIRA Pharmaceuticals Inc (NASDAQ:MIRA) shares are trading significantly higher on Thursday following the announcement of new preclinical data for its lead candidate Mira-55.
What Happened: MIRA announced preclinical study results showing that oral Mira-55 normalized pain and significantly reduced inflammation in an animal model of inflammatory pain, outperforming injected morphine.